Cargando…

Association between Changes in the Patterns of Antinuclear Autoantibodies during Immune Checkpoint Inhibition Therapy and the Development of Severe Immune Related Adverse Events

Immune-related adverse events (irAEs) are unpredictable autoimmune-like toxicities induced by immune checkpoint inhibitors (ICI). irAEs are a consequence of a breakdown in self-tolerance. ICIs can induce autoantibody formation, and the presence of antinuclear autoantibodies (ANAs) has been reported...

Descripción completa

Detalles Bibliográficos
Autores principales: Alserawan, Leticia, Anguera, Geòrgia, Zamora Atenza, Carlos, Serra López, Jorgina, Martínez-Martínez, Laura, Riudavets Melià, Mariona, Sullivan, Ivana, Barba Joaquin, Andrés, Majem Tarruella, Margarita, Vidal, Silvia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604501/
https://www.ncbi.nlm.nih.gov/pubmed/36293498
http://dx.doi.org/10.3390/ijms232012641
_version_ 1784817829941346304
author Alserawan, Leticia
Anguera, Geòrgia
Zamora Atenza, Carlos
Serra López, Jorgina
Martínez-Martínez, Laura
Riudavets Melià, Mariona
Sullivan, Ivana
Barba Joaquin, Andrés
Majem Tarruella, Margarita
Vidal, Silvia
author_facet Alserawan, Leticia
Anguera, Geòrgia
Zamora Atenza, Carlos
Serra López, Jorgina
Martínez-Martínez, Laura
Riudavets Melià, Mariona
Sullivan, Ivana
Barba Joaquin, Andrés
Majem Tarruella, Margarita
Vidal, Silvia
author_sort Alserawan, Leticia
collection PubMed
description Immune-related adverse events (irAEs) are unpredictable autoimmune-like toxicities induced by immune checkpoint inhibitors (ICI). irAEs are a consequence of a breakdown in self-tolerance. ICIs can induce autoantibody formation, and the presence of antinuclear autoantibodies (ANAs) has been reported in patients who developed irAEs. Our goal was to compare ANA patterns by indirect immunofluorescence at different timepoints before (baseline) and after the initiation of ICI treatment and to analyze the role of ANA pattern changes as predictors of irAEs. This is a 2-year-follow-up prospective study of 152 consecutive patients with solid tumors treated with anti-PD-(L)1 blockade agents. They were included from September 2018 until March 2020 in the Hospital de la Santa Creu I Sant Pau (Barcelona, Spain). We grouped patients into three groups: ANA de novo (patients who showed new ANA patterns at any time after ICI initiation), ANA (ANA positive at baseline without changes in the ANA patterns after initiation of treatment) and non-ANA (ANA negative at baseline and after ICI initiation). We did not find any association between the appearance of ANAs and irAE rates or the number and types of irAEs. However, patients in the ANA de novo group showed higher severe irAE rates (grade ≥ 3) than the other groups. Additionally, in most of the patients with severe irAEs (83.3%), changes in ANA patterns preceded irAE onset. In conclusion, we found ANA induction during ICI therapies in 22 patients and our results suggest that the appearance of ANAs may predict the severity of the irAE.
format Online
Article
Text
id pubmed-9604501
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96045012022-10-27 Association between Changes in the Patterns of Antinuclear Autoantibodies during Immune Checkpoint Inhibition Therapy and the Development of Severe Immune Related Adverse Events Alserawan, Leticia Anguera, Geòrgia Zamora Atenza, Carlos Serra López, Jorgina Martínez-Martínez, Laura Riudavets Melià, Mariona Sullivan, Ivana Barba Joaquin, Andrés Majem Tarruella, Margarita Vidal, Silvia Int J Mol Sci Article Immune-related adverse events (irAEs) are unpredictable autoimmune-like toxicities induced by immune checkpoint inhibitors (ICI). irAEs are a consequence of a breakdown in self-tolerance. ICIs can induce autoantibody formation, and the presence of antinuclear autoantibodies (ANAs) has been reported in patients who developed irAEs. Our goal was to compare ANA patterns by indirect immunofluorescence at different timepoints before (baseline) and after the initiation of ICI treatment and to analyze the role of ANA pattern changes as predictors of irAEs. This is a 2-year-follow-up prospective study of 152 consecutive patients with solid tumors treated with anti-PD-(L)1 blockade agents. They were included from September 2018 until March 2020 in the Hospital de la Santa Creu I Sant Pau (Barcelona, Spain). We grouped patients into three groups: ANA de novo (patients who showed new ANA patterns at any time after ICI initiation), ANA (ANA positive at baseline without changes in the ANA patterns after initiation of treatment) and non-ANA (ANA negative at baseline and after ICI initiation). We did not find any association between the appearance of ANAs and irAE rates or the number and types of irAEs. However, patients in the ANA de novo group showed higher severe irAE rates (grade ≥ 3) than the other groups. Additionally, in most of the patients with severe irAEs (83.3%), changes in ANA patterns preceded irAE onset. In conclusion, we found ANA induction during ICI therapies in 22 patients and our results suggest that the appearance of ANAs may predict the severity of the irAE. MDPI 2022-10-20 /pmc/articles/PMC9604501/ /pubmed/36293498 http://dx.doi.org/10.3390/ijms232012641 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Alserawan, Leticia
Anguera, Geòrgia
Zamora Atenza, Carlos
Serra López, Jorgina
Martínez-Martínez, Laura
Riudavets Melià, Mariona
Sullivan, Ivana
Barba Joaquin, Andrés
Majem Tarruella, Margarita
Vidal, Silvia
Association between Changes in the Patterns of Antinuclear Autoantibodies during Immune Checkpoint Inhibition Therapy and the Development of Severe Immune Related Adverse Events
title Association between Changes in the Patterns of Antinuclear Autoantibodies during Immune Checkpoint Inhibition Therapy and the Development of Severe Immune Related Adverse Events
title_full Association between Changes in the Patterns of Antinuclear Autoantibodies during Immune Checkpoint Inhibition Therapy and the Development of Severe Immune Related Adverse Events
title_fullStr Association between Changes in the Patterns of Antinuclear Autoantibodies during Immune Checkpoint Inhibition Therapy and the Development of Severe Immune Related Adverse Events
title_full_unstemmed Association between Changes in the Patterns of Antinuclear Autoantibodies during Immune Checkpoint Inhibition Therapy and the Development of Severe Immune Related Adverse Events
title_short Association between Changes in the Patterns of Antinuclear Autoantibodies during Immune Checkpoint Inhibition Therapy and the Development of Severe Immune Related Adverse Events
title_sort association between changes in the patterns of antinuclear autoantibodies during immune checkpoint inhibition therapy and the development of severe immune related adverse events
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604501/
https://www.ncbi.nlm.nih.gov/pubmed/36293498
http://dx.doi.org/10.3390/ijms232012641
work_keys_str_mv AT alserawanleticia associationbetweenchangesinthepatternsofantinuclearautoantibodiesduringimmunecheckpointinhibitiontherapyandthedevelopmentofsevereimmunerelatedadverseevents
AT anguerageorgia associationbetweenchangesinthepatternsofantinuclearautoantibodiesduringimmunecheckpointinhibitiontherapyandthedevelopmentofsevereimmunerelatedadverseevents
AT zamoraatenzacarlos associationbetweenchangesinthepatternsofantinuclearautoantibodiesduringimmunecheckpointinhibitiontherapyandthedevelopmentofsevereimmunerelatedadverseevents
AT serralopezjorgina associationbetweenchangesinthepatternsofantinuclearautoantibodiesduringimmunecheckpointinhibitiontherapyandthedevelopmentofsevereimmunerelatedadverseevents
AT martinezmartinezlaura associationbetweenchangesinthepatternsofantinuclearautoantibodiesduringimmunecheckpointinhibitiontherapyandthedevelopmentofsevereimmunerelatedadverseevents
AT riudavetsmeliamariona associationbetweenchangesinthepatternsofantinuclearautoantibodiesduringimmunecheckpointinhibitiontherapyandthedevelopmentofsevereimmunerelatedadverseevents
AT sullivanivana associationbetweenchangesinthepatternsofantinuclearautoantibodiesduringimmunecheckpointinhibitiontherapyandthedevelopmentofsevereimmunerelatedadverseevents
AT barbajoaquinandres associationbetweenchangesinthepatternsofantinuclearautoantibodiesduringimmunecheckpointinhibitiontherapyandthedevelopmentofsevereimmunerelatedadverseevents
AT majemtarruellamargarita associationbetweenchangesinthepatternsofantinuclearautoantibodiesduringimmunecheckpointinhibitiontherapyandthedevelopmentofsevereimmunerelatedadverseevents
AT vidalsilvia associationbetweenchangesinthepatternsofantinuclearautoantibodiesduringimmunecheckpointinhibitiontherapyandthedevelopmentofsevereimmunerelatedadverseevents